Standard BioTools Inc. has entered into a definitive agreement to sell its Microfluidics business segment to ARCHIMED, an investment firm focused on the healthcare industry. The company stated this transaction is an important step in its strategic plan.
Key Details
- Asset Sold: The company's Microfluidics business.
- Buyer: ARCHIMED, a healthcare-focused investment firm.
- Timeline: The transaction is expected to close in approximately 30 days, subject to customary closing conditions.
- Financials: The financial terms of the sale were not disclosed in the filing.